| CB2 / CNR2 : Druggable immune-enriched cannabinoid receptor involved in microglia, inflammation, immune-cell signaling, pain, neuroprotection, and tumor-immune regulation.
| Field |
Suggested Entry |
| Target |
CB2 / CNR2 |
| Full Name |
Cannabinoid receptor type 2 |
| Target Class |
G-protein-coupled receptor; Gi/o-coupled cannabinoid receptor |
| Primary Biology |
Immune modulation, microglial activation, inflammatory signaling, cytokine regulation, leukocyte behavior, pain/inflammation signaling |
| Cancer Relevance |
Medium and context-dependent: may suppress inflammation or tumorigenesis in some settings, but may also support immune suppression or tumor progression depending on tumor type and immune context |
| AD Relevance |
Medium-high: microglial CB2 activation is a promising neuroinflammation strategy, with encouraging preclinical evidence in AD models but limited clinical validation |
| Therapeutic Direction |
Usually selective CB2 agonism/modulation for neuroinflammation and inflammatory disease; cancer direction is tumor-context-dependent |
| Key Product Links |
β-caryophyllene, PEA, CBD/cannabinoid-system modulators, endocannabinoids, omega-3-derived lipid mediators |
|